Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13840734 | 1.00 | ADRB2 (0.62) | ADRB2CHRM3 | |
| SCHEMBL13840735 | 0.95 | ADRB2 (0.58) | ADRB2CHRM3 | |
| SCHEMBL3918557 | 0.95 | ADRB2 (0.58) | ADRB2CHRM3 | |
| SCHEMBL3922097 | 0.93 | ADRB2 (0.60) | ADRB2CHRM3 | |
| SCHEMBL3915467 | 0.92 | ADRB2 (0.55) | ADRB2CHRM3 | |
| SCHEMBL13840733 | 0.92 | ADRB2 (0.55) | ADRB2CHRM3 | |
| SCHEMBL13840728 | 0.91 | ADRB2 (0.75) | ADRB2CHRM3 | |
| SCHEMBL3917030 | 0.91 | ADRB2 (0.75) | ADRB2CHRM3 | |
| SCHEMBL3925018 | 0.91 | ADRB2 (0.60) | ADRB2CHRM3 | |
| SCHEMBL3917151 | 0.90 | ADRB2 (0.62) | ADRB2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730141-B1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2009-05-27 | — | — | EP | claimed |
| EP-1730141-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-12-13 | — | — | EP | claimed |
| WO-2005092887-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | claimed |
| EP-1730141-B1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2009-05-27 | — | — | EP | disclosed |
| US-7538141-B2 | Compounds for the treatment of diseases | PFIZER INC. | 2009-05-26 | — | — | US | disclosed |
| EP-1730141-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-12-13 | — | — | EP | disclosed |
| US-20050222128-A1 | Compounds for the treatment of diseases | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| WO-2005092887-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222128-A1 | Compounds for the treatment of diseases | LTC4S, LTB4R2, CYP11B2 | ADRB2 639/4885CHRM3 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.